![Eric Easom](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Eric Easom
Vorstandsvorsitzender bei
AN2 THERAPEUTICS, INC.
Vermögen: 7 Mio $ am 30.06.2026
Profil
Eric Easom is the founder of AN2 Therapeutics, Inc., founded in 2017, where the title held is Chairman, President & Chief Executive Officer since 2024.
Current jobs include Director at Resilient Biotics, Inc. since 2019 and Director at Chagas Disease Foundation since 2018.
Former jobs include Senior Director-Business Development & Marketing at InteKrin Therapeutics, Inc. from 2007 to 2009, Director at Infectious Disease Research Institute from 2013 to 2014, and Vice President-Neglected Diseases at Anacor Pharmaceuticals LLC from 2009 to 2017.
Education includes undergraduate studies at the University of Louisville and an MBA from Kelley School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 31.03.2026 | 1’357’825 ( 3.77% ) | 7 Mio $ | 30.06.2026 |
Aktive Positionen von Eric Easom
| Unternehmen | Position | Beginn |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Vorstandsvorsitzender | 01.11.2019 |
Chagas Disease Foundation | Direktor/Vorstandsmitglied | 01.06.2018 |
Resilient Biotics, Inc.
 Resilient Biotics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops microbiome-based therapeutics | Direktor/Vorstandsmitglied | 01.02.2019 |
Ehemalige bekannte Positionen von Eric Easom
| Unternehmen | Position | Ende |
|---|---|---|
| ANACOR PHARMACEUTICALS INC | Corporate Officer/Principal | 01.06.2017 |
Infectious Disease Research Institute
 Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Vorsitzender | 01.01.2013 |
InteKrin Therapeutics, Inc.
 InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for metabolic and immune disorders | Vertrieb & Marketing | 01.01.2009 |
Ausbildung von Eric Easom
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
28
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics for metabolic and immune disorders | Health Technology |
University of Louisville
 University of Louisville Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anacor Pharmaceuticals LLC
 Anacor Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a bio pharmaceutical company | Health Technology |
Infectious Disease Research Institute
Infectious Disease Research Institute Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biotechnology products to control infectious diseases | Commercial Services |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Resilient Biotics, Inc.
Resilient Biotics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops microbiome-based therapeutics | Commercial Services |
AN2 Therapeutics, Inc.
 AN2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics | Health Technology |
Chagas Disease Foundation |
